

**For professional/qualified investors only**

## **Twelve Capital Research Spotlight**

### **The current opportunity in the US life insurance sector**

#### **Valuation Update**

Twelve reviews the results of the Q2 2018 reporting season for US life insurers and the overall valuation of these companies. Analysis shows valuations seem to be pricing in pessimism which is neither justified by company-specific fundamentals nor the overall current macro environment.

Key takeaways are:

- Operating results for Q2 were relatively benign, apart from a few names that outperformed on big earnings beats and/or positive outlook comments (Primerica, Athene, Aflac). Other companies showed substantial moves on non-earnings, company-specific considerations (CNO Financial Group, Unum).
- Overall stock performance for the group over the reporting season was in line with other financials, i.e. slightly ahead of the wider market. Results were not quite strong enough to revive investor enthusiasm for the sector, however.
- These companies' valuations are in line with historical averages, but depressed relative to elevated overall market valuations.
- US life insurers now trade at around 50% of the S&P 500 Index's P/E rather than at 60% - on a historical basis, this valuation is consistent with the US being in recession or 10-year Treasury yields below 2%, neither of which are the case.
- Merger activity in the US life insurance sector has been relatively quiet year-to-date. However, Twelve believes that conditions continue to support a pick-up in acquisition and restructuring activities.
- US life insurers' investment income is benefiting from higher yields, overall equity volatility remains navigable – all of which support the belief that valuations for the sector should improve.


#### **A relatively neutral Q2 2018 reporting season**

Performance of US life insurers during the Q2 2018 reporting season was mixed, but was essentially in line with other major financials groups slightly ahead of the S&P 500 Index<sup>1</sup>, which was up 1%. An overview is shown in Figure 1. There were substantial movements driven by considerations around company exposures to long-term care insurance risks as we got our first look at a completed annual reserve review (Prudential), saw a meaningful reinsurance transaction (CNO Financial Group), and received interim guidance ahead of another important reserve review to be completed in Q3 (Unum).

---

<sup>1</sup> American stock market index based on the market capitalisations of 500 large companies having common stock listed on the NYSE or NASDAQ.

**Figure 1: Earnings season stock performance**



Source: Bloomberg, Twelve Capital. As at 14 August 2018.

Otherwise, stock movements were largely name-specific with three companies reporting results meaningfully ahead of investors' expectations (Primerica, Athene, Aflac). Overall, results were generally in line, although not sufficiently positive to outweigh broader macro fears and drive investors back to the group in a strong way.

## Sector valuations look compelling relative to overall markets and the level of interest rates

At a price/earnings ratio (P/E) of 8.5 times, US life insurers<sup>2</sup> are trading at a valuation roughly in line with the long-term average. However, relative to a richly-valued overall market, the sector could be viewed as trading at a discount. As shown in Figure 2, at 51% of the S&P 500 Index P/E, this is historically around the lowest level at which the group has typically traded outside severely stressed macro environments. Other points in time when this valuation level have been seen post-crisis were during the first and second Eurozone crises and the early 2016 China-driven risk-off market.

<sup>2</sup> Represented by the S&P 500 Life sub-index. Standard and Poor's 500 Life & Health Insurance Index is a capitalisation-weighted index containing companies providing primarily life, disability, indemnity or supplemental health insurance.

**Figure 2: US life insurers' P/E Ratio – divergence relative to S&P 500 Index P/E**




Source: Bloomberg, Twelve Capital. 31 December 2004 – 10 August 2018.

Legend: S5LIFE: S&P 500 Life & Health Insurance Index. SPX: S&P 500 Index. USGG10YR: US Generic Govt 10 Year Yield

Historically, there has been a high correlation between the yield on the US 10-year Treasury and the relative valuation of the US life insurers. This is demonstrated in Figures 2 and 3. Since 2004, this relationship only broke down during the 2007/2008 recession (as represented by the yellow points in Figure 3) and for a short period early in the post-recession recovery (shown by the few blue points below the shaded region in Figure 3).

**Figure 3: US life insurance sector P/E ratio (relative to S&P 500 Index P/E) vs. US 10-year Treasury yield, since YE'2014**



Source: Bloomberg, Twelve Capital. 31 December 2004 – 10 August 2018.

With the underperformance of US life insurers this year (as per the green points in Figure 3), the group now trades at a valuation consistent with the US currently being in recession, or as if the 10-year Treasury yield were still below 2%. Were the historical relationship to hold, Twelve would expect the group to trade at around 60% of the S&P 500 Index's P/E, rather than the current level of approximately 50%. This would imply an average P/E of about 10 times versus the current level of 8.5 times, or about 17% higher.

## M&A and restructuring activity – currently quiet but has the potential to pick up

Merger and acquisition (M&A) activity has been quiet so far this year, but conditions support a potential pick-up. Recent items have included:

- Annuity insurer American Equity Life holding preliminary discussions regarding a potential transaction. The stock trades at a take-out valuation, though so far there has not been a reported bid.
- Annuity insurer and active acquirer Athene described their transaction pipeline as being as robust as they have ever seen it and noted a particular appetite for large, complex structured transactions and acknowledged an interest in partnering with private equity sponsor Apollo on transactions involving long-term care insurance. This further fuelled speculation that the companies are looking at General Electric's insurance business. In July, it was reported that Voya had hired Morgan Stanley to seek a buyer for their life insurance business, potentially worth in excess of USD 1 billion. It is expected that there are likely to be a number of bidders for this asset.
- Meanwhile, Reinsurance Group of America, a life reinsurer had a quiet quarter in terms of acquisitions. However, the company revealed a positive outlook for closed block deals, weighted towards the US but seeing opportunities in Europe as well, for a range of sizes and structures. The company reported USD 1.2 billion of excess capital to deploy on block acquisitions.

### Summary & conclusion

Twelve does not see a justification for this valuation gap given the US life insurers' recent reported earnings due to:

- Higher yields across the yield curve are lifting pressures on these companies' investment income.
- Equity market volatility has risen from historic lows, but remain generally navigable.
- Sales trends are mixed, but the overall growth outlook for the group is relatively consistent with long-term trends for this mature business, and some areas justify optimism for improvement such as wage inflation gearing in group benefits and headwinds fading in annuities.
- While the overall balance sheet credit environment warrants some caution, there are no indicators at present to suggest recession-level credit risk concerns on the horizon.

Thus Twelve continues to see limited downside for the group from current levels in the absence of a broader macro downturn, which already appears to be partly-priced into the sector.

## Directory of company names

Ticker	Company Name	Market Cap (USDm)	P/E Ratio	P/BVPS	Dividend Yield	EPS Growth
<b>US Life Insurance Companies</b>						
AEL	American Equity Investment Life Holding Co	3'392	11.2x	1.40x	0.75%	5.3%
AFL	Aflac Inc.	36'025	11.6x	1.52x	2.23%	2.3%
AMP	Ameriprise Financial Inc	20'128	9.3x	3.58x	2.50%	10.0%
ATH	Athene Holding Ltd	9'522	7.4x	1.18x	0.00%	14.9%
BHF	Brighthouse Financial Inc	5'051	4.8x	0.35x	0.00%	12.7%
CNO	CNO Financial Group Inc	3'639	10.7x	0.82x	1.76%	10.6%
EQH	AXA Equitable Holdings Inc	12'723	6.1x	0.41x	1.27%	11.4%
LNC	Lincoln National Corp	14'418	7.5x	0.95x	2.02%	10.5%
MET	MetLife Inc	46'568	8.9x	0.91x	3.54%	5.6%
PFG	Principal Financial Group Inc	16'085	9.6x	1.38x	3.72%	6.0%
PRI	Primerica Inc	5'242	16.0x	3.75x	0.83%	14.1%
PRU	Prudential Financial Inc	41'562	7.9x	0.86x	3.61%	6.3%
RGA	Reinsurance Group of America Inc	9'268	11.5x	1.08x	1.49%	17.4%
UNM	Unum Group	7'937	8.0x	0.84x	2.66%	19.7%
VOYA	Voya Financial Inc	8'138	10.4x	0.97x	0.09%	24.2%
<b>Other stocks mentioned in this report</b>						
GE	General Electric Co	109'768	12.1x	1.99x	3.80%	11.3%
LGEN	Legal & General Group PLC	19'589	8.9x	1.98x	6.38%	5.9%
RNR	RenaissanceRe Holdings Ltd	5'298	12.2x	1.26x	1.00%	-18.3%

Source: Bloomberg. As at 22 August 2018.

**Twelve Capital AG**

Dufourstrasse 101  
8008 Zurich, Switzerland  
Phone +41 (0)44 5000 120

**Twelve Capital (UK) Ltd**

Moss House, 15-16 Brook's Mews  
London W1K 4DS, United Kingdom  
Phone: +44 (0)203 856 6760

**Twelve Capital US Inc.**

1010 Northern Blvd  
Great Neck, NY 10021  
United States of America

info@twelvecapital.com  
www.twelvecapital.com

**About Twelve Capital**

Twelve Capital is an independent investment manager specialising in insurance investments for institutional clients. As at 30 June 2018, the firm had approximately USD 4.5bn in assets under management. Twelve Capital's investment expertise covers the entire balance sheet of insurance companies, including Insurance Bonds, Insurance Private Debt, Catastrophe Bonds, Private Insurance-Linked Securities and Insurance Equity. The firm also structures portfolios of its Best Ideas. Twelve Capital was founded in October 2010 and has offices in Zurich, London and New York.

**Disclaimer**

This material has been furnished to you solely upon request and may not be reproduced or otherwise disseminated in whole or in part without prior written consent from Twelve Capital AG, Twelve Capital (UK) Limited or their affiliates (collectively, "Twelve Capital"). The information herein is based solely on the opinions of Twelve Capital and includes information based on estimates and should in no circumstances be relied upon. All information and opinions contained in this document may be subject to change without notice. Source for all data and charts (if not indicated otherwise): Twelve Capital. Twelve Capital does not assume any liability regarding incorrect or incomplete information (whether received from public sources or whether prepared internally or not). This material does not constitute a prospectus, a request/offer, nor a recommendation of any kind, e.g. to buy/subscribe or sell/redeem investment instruments or to perform other transactions. The investment instruments mentioned herein involve significant risks including the possible loss of the amount invested as described in detail in the offering memorandum(s) (where applicable) for these instruments which will be available upon request. Past performance is no indication or guarantee of future performance. The products and services described herein are not available nor offered to US persons and may not (and will not) be publicly offered to persons residing in any country restricting the offer of such products or services. In particular, any products have not been licensed by the Swiss Financial Market Supervisory Authority (the "FINMA") for distribution to non-qualified investors pursuant to Art. 120 para. 1 to 3 of the Swiss Federal Act on Collective Investment Schemes of 23 June 2006, as amended ("CISA"). Accordingly, pursuant to Art. 120 para. 4 CISA, the investment instruments may only be offered and this material may only be distributed in or from Switzerland to qualified investors as defined in the CISA and its implementing ordinance. Further, the investment instruments may be sold under the exemptions of Art. 3 para. 2 CISA. Investors in the investment instruments do not benefit from the specific investor protection provided by CISA and the supervision by the FINMA in connection with the licensing for distribution. Where distribution is to EU members states such distribution is carried out by Twelve Capital (UK) Limited in accordance with the terms of its authorisation and regulation by the Financial Conduct Authority. Twelve Capital AG is incorporated in Switzerland, registered number 130.3.015.932-9, registered office: Dufourstrasse 101, 8008 Zurich. Twelve Capital (UK) Limited is Incorporated in England & Wales: company number 08685046, registered office: Moss House, 15-16 Brook's Mews, London, W1K 4DS and is also registered as a Commodity Pool Operator by the Commodities Futures Trading Commission in the United States of America.